Fig. 3

Oxaliplatin dose- and time-dependently reduces the NAD+/NADH ratio in HCT116 p53-wild-type (a) and p53-null (b) cells. Cells were treated with ddH2O or oxaliplatin, and the NAD+ and NADH levels in cell extracts were quantified based on the optical density at 450 nm, the NAD+/NADH ratio was calculated. Values (mean ± SEs) were obtained from at least three independent experiments